 1.  Short title This Act may be cited as the  Gluten in Medicine Disclosure Act of 2021 .
 2.  Labeling of drugs with an ingredient made from a gluten-containing grain  (a)  Misbranding Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (gg)  If it is a drug—  (1)  that is intended for human use;  (2)  that contains an ingredient that is derived directly or indirectly from a gluten-containing grain (including wheat, barley, rye, and their crossbred hybrids); and  (3)  whose label fails—  (A)  to state that the drug contains such an ingredient; and  (B)  to identify each such ingredient and the type of gluten-containing grain from which it is derived.  .  (b)  Applicability  Section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) of this section, shall apply beginning on the sooner of—  (1)  a date to be determined by the Secretary of Health and Human Services; and  (2)  the date that is 2 years after the date of the enactment of this Act. 
